GM1 Liposomal Composition Patent for Parkinson's Disease Treatment
Summary
INNOMEDICA HOLDING AG has been granted US Patent US12611419B2 for a method of treating Parkinson's disease using a liposomal composition comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1. The patent, granted April 28, 2026, contains 17 claims and covers the therapeutic composition and its use in the specified treatment method.
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
INNOMEDICA HOLDING AG has been granted a US patent covering a method of treating Parkinson's disease using a liposomal composition. The composition comprises sphingomyelin in a lipid bilayer with a therapeutically effective amount of GM1. The patent was granted April 28, 2026, and contains 17 claims.
Competitors developing liposomal GM1 formulations for neurological applications should be aware that this patent may restrict freedom to operate in this specific treatment space without a license from the assignee.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Liposomal composition for use in a method of treating Parkinson's disease
Grant US12611419B2 Kind: B2 Apr 28, 2026
Assignee
INNOMEDICA HOLDING AG
Inventors
Stéfan Jonathan Halbherr, Camille Françoise Peitsch
Abstract
A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.
CPC Classifications
A61P 25/28
Filing Date
2023-03-09
Application No.
18181163
Claims
17
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.